Latest Breaking News On - Eiger biopharmaceuticals inc - Page 6 : comparemela.com

Eiger BioPharmaceuticals (NASDAQ:EIGR) and Humacyte (NASDAQ:HUMA) Financial Analysis

Eiger BioPharmaceuticals (NASDAQ:EIGR) and Humacyte (NASDAQ:HUMA) Financial Analysis
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesPalo altoNorth carolinaHumacyte incEiger biopharmaceuticals incEiger biopharmaceuticalsGet free reportGiven eiger biopharmaceuticalEiger biopharmaceuticals daily

StockNews com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research note issued to investors on Monday. The firm issued a sell rating on the biotechnology company’s stock. Eiger BioPharmaceuticals Stock Down 0.3 % EIGR stock opened at $5.80 on Monday. The firm has a 50 day moving average of $6.89 […]

United statesEiger biopharmaceuticals company profileMorgan stanleyVanguard group incAmeriprise financial incEiger biopharmaceuticals incBarclays plcEiger biopharmaceuticalsFree reportBiopharmaceuticals stock downStreet corpGet free reportEiger biopharmaceuticals dailyNasdaq eigrInitiated coverageStocknews com

Short Interest in Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR) Drops By 7 3%

Short Interest in Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR) Drops By 7 3%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesAmerica corpSequoia financial advisorsEiger biopharmaceuticals incEiger biopharmaceuticalsGet free reportFinancial advisorsEiger biopharmaceuticals daily

StockNews com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a report published on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Eiger BioPharmaceuticals Stock Performance Shares of EIGR stock opened at $6.11 on Friday. The company has a debt-to-equity ratio of 2.64, a quick ratio of […]

United statesMorgan stanleyEiger biopharmaceuticals incAmeriprise financial incBarclays plcVanguard group incEiger biopharmaceuticalsFree reportGet free reportStreet corpEiger biopharmaceuticals dailyNasdaq eigrInitiated coverageStocknews com

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone.

Aljanae reynoldsZokinvy lonafarnibSylvia wheelerDavid apelianProgeria research foundationUniversity of washingtonPrnewswire eiger biopharmaceuticals incAnges incMinistry of healthEiger biopharmaceuticals incImportant safety informationBreakthrough therapyPrivate securities litigation reform actQuarterly reportProduct characteristicsGilford progeria